Abstracts Archive - Page 827 of 2425 - ACR Meeting Abstracts

Abstract Number: 1029 • 2019 ACR/ARP Annual Meeting
Epstein-Barr Virus Interleukin 10 in SLE Pathogenesis
Neelakshi R. Jog¹, Wade DeJager ¹, Joel Guthridge ² and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a systemic autoimmune disease characterized by periods of elevated and suppressed disease activity. Epstein Barr Virus (EBV) has been…
Abstract Number: 1030 • 2019 ACR/ARP Annual Meeting
DNA Methylation Changes Are Associated with Particulate Matter 2.5 Exposure in SLE Patients
Olivia Solomon¹, Cristina Lanata ², Maria Dall'Era ², Jinoos Yazdany ³, Patricia Katz ², Laura Trupin ², Kim Taylor ⁴, Joanne Nititham ², Brooke Rhead ⁵, Lindsey Criswell ⁶ and Lisa Barcellos ⁷, ¹University of California, Berkeley, Oakland, ²University of California, San Francisco, san francisco, CA, ³UCSF Division of Rheumatology, San Francisco, CA, ⁴UCSF, San Francisco, CA, ⁵University of California, Berkeley, Berkeley, CA, ⁶University of California, San Francisco, San Francisco, ⁷University of California, Berkeley, Berkeley
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical manifestations. Epigenetic changes, including DNA methylation, have been implicated in SLE; specifically, differences…
Abstract Number: 1031 • 2019 ACR/ARP Annual Meeting
Expanded Circulating Peripheral Helper T Cells Are Associated with B Cell Differentiation in Systemic Lupus Erythematosus
Ayako Makiyama¹, Asako Chiba ², Daisuke Noto ¹, Goh Murayama ³, Tomohiro Mizuno ⁴, Taiga Kuga ⁵, Ken Yamaji ⁵, Naoto Tamura ⁵ and Sachiko Miyake ², ¹Juntendo University School of Medicine, Tokyo, Japan, ²Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rhumatology, Juntendo University School of Medicine, Tokyo, Japan, ⁴Department of Immunlogy, Juntendo University School of Medicine, Tokyo, Japan, ⁵Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Autoreactive T-B cell interactions in lymphoid tissue have been thought to play a crucial role in the autoantibody production in systemic lupus erythematosus (SLE).…
Abstract Number: 1032 • 2019 ACR/ARP Annual Meeting
Lipocalin-2 Exacerbates Lupus Nephritis by Promoting Th1 Cell Differentiation
Weiwei Chen ¹ and Lingyun Sun¹, ¹Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China (People's Republic)
Background/Purpose: Kidney involvement is a major concern in systemic lupus erythematosus (SLE). Lipocalin-2 (LCN2) has been indicated as a potential marker of the presence and…
Abstract Number: 1033 • 2019 ACR/ARP Annual Meeting
Mass Cytometric Immunophenotyping Highlights a Dysregulated T cell-B Cell Axis in Patients with New-onset Lupus
Ye Cao¹, Stephen Alves ², Corine Sinnette ³, Cameron Speyer ³, Gregory Keras ¹, Yujie Qu ², Joshua Keegan ⁴, James Lederer ⁴, Deepak Rao ³ and Karen Costenbader ³, ¹Brigham and Women's Hospital, Boston, ²Merck, boston, ³Brigham and Women's Hospital, Boston, MA, ⁴BWH, Boston
Background/Purpose: The immune cell subsets most altered early in SLE disease course remain unclear. Defining abnormalities in lymphocyte populations in patients with new-onset SLE may…
Abstract Number: 1034 • 2019 ACR/ARP Annual Meeting
Circulating MicroRNAs as Potential Biomarkers for Monitoring the Response to In Vivo Treatment with Rituximab in Systemic Lupus Erythematosus
Carlos Perez-Sanchez¹, Irene Cecchi ², Laura Pérez-Sanchez ³, Alejandra Patiño-Trives ⁴, Nuria Barbarroja ⁵, Maria Luque-Tevar ⁴, Alejandro Ibañez-Costa ⁴, Ivan Arias de la Rosa ⁶, Maria del Carmen Abalos-Aguilera ⁴, Rafaela Ortega ⁴, Alejandro Escudero ⁷, Massimo Radin ², Savino Sciascia ⁸, Mª Ángeles Aguirre-Zamorano ⁷, Eduardo Collantes-Estevez ⁶ and Chary Lopez-Pedrera ⁴, ¹Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²University of Turin, Turin, Italy, ³MIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁴IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ⁵University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁶University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ⁷IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, ⁸Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Torino, Italy
Background/Purpose: Recent studies have highlighted the potential role of microRNAs (miRNAs) as diagnostic and prognostic biomarkers in Systemic Lupus Erythematosus (SLE). While Rituximab (RTX) represents…
Abstract Number: 1035 • 2019 ACR/ARP Annual Meeting
Examining the Transcriptional Impact of Liganded ERα in the Inflammatory Milieu of Systemic Lupus Erythematosus
Mara Lennard Richard¹, Melissa Cunningham ², Betty Tsao ³ and Gary Gilkeson ⁴, ¹Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, ³Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, ⁴Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic lupus erythematosus (SLE) disproportionally affects females (9:1) over males. Despite significant research effort, the exact mechanisms behind this compelling sex bias are undefined.…
Abstract Number: 1036 • 2019 ACR/ARP Annual Meeting
RNA Sequencing of PBMCs Reveals Estrogen-Mediated Upregulation of Micro-RNA Processing Machinery
Nicholas Young¹, Kyle Jablonski ², Ifeoma Okafor ³, Emily Schwarz ³, Peter Harb ³, Caitlin Henry ³, Lai-Chu Wu ³ and Wael Jarjour ⁴, ¹The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, OH, ²The Ohio State University Wexner Medical Center, Division of Immunology and Rheumatology, Columbus, ³Ohio State College of Medicine, Columbus, ⁴Ohio State College of Medicine, Columbus, OH
Background/Purpose: Studies examining intracellular micro-RNA (miR) expression in PBMCs of patients with Systemic Lupus Erythematous (SLE) have identified distinct disease-associated changes in expression. We have…
Abstract Number: 1037 • 2019 ACR/ARP Annual Meeting
Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Sujata Ganguly¹, Sanjukta Majumder ², Hafis Muhammed ³, Amita Aggarwal ⁴ and Ramnath Misra ², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ³SGPGI, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Complement activation is one of the important pathogenic features of lupus nephritis and low serum complements are conventionally used to monitor disease activity in…
Abstract Number: 1038 • 2019 ACR/ARP Annual Meeting
Distinct Cell-bound Complement Activation Signatures Are Observed in Patients with Systemic Lupus Erythematosus
Rebecca Schriefer ¹, Gabriel Arguelles ¹, John Atkinson ¹, Dennis Hourcade ¹ and Alfred Kim¹, ¹Washington University School of Medicine, Saint Louis, MO
Background/Purpose: Cell-bound complement activation products (CB-CAPs) have previously been shown to associate with SLE disease activity, but only a small fraction of total CB-CAPs has…
Abstract Number: 1039 • 2019 ACR/ARP Annual Meeting
Molecular Profiling Identifies Immunologic Subgroups and Informs Mechanism of Action of Baricitinib in SLE
Thomas Dörner¹, Yoshiya Tanaka ², Michelle Petri ³, Josef Smolen ⁴, Daniel Wallace ⁵, Ernst Dow ⁶, Damiano Fantini ⁶, Richard Higgs ⁶, Guilherme Rocha ⁶, Brenda Crowe ⁶, Robert Benschop ⁶, Adam Abel ⁶, Nicole Byers ⁶, Maria Silk ⁶, Stephanie de Bono ⁶ and Robert Hoffman ⁶, ¹Charite Universitätsmedizin Berlin and DRFZ, Berlin, Germany, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Medical University of Vienna, Vienna, Austria, ⁵Cedars-Sinai Medical Center/University California at Los Angeles, Los Angeles, CA, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Baricitinib is an oral selective Janus kinase (JAK) 1 and JAK2 inhibitor. In the Phase II, 24-week, randomized, placebo-controlled, double-blind study JAHH (NCT02708095), once-daily…
Abstract Number: 1040 • 2019 ACR/ARP Annual Meeting
Proposition of a Novel Animal Model of Systemic Sclerosis Induced by Type V Collagen in C57BL/6 Mice Reproducing Fibrosis, Vasculopathy and Autoimmunity
Walcy Teodoro¹, Ana Paula Velosa ², Zelita Aparecida Queiroz ¹, Lais Araujo ³, Sergio Catanozi ¹, Antonio dos Santos Filho ⁴, Cleonice Bueno ⁴, Margarete Vendramini ⁴, Sandra Moraes Fernezlian ¹, Esmeralda Eher ⁴, Jurandir Tomaz de Miranda ¹, Fernanda Lopes ⁴, Sandra G. Pasoto ⁵, Percival Degrava Sampaio-Barros ⁶ and Vera Luiza Capelozzi ¹, ¹Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Sao Paulo, Brazil, ³Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, São Paulo, Sao Paulo, Brazil, ⁴Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, ⁶Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Brazil, Sao Paulo, Brazil
Background/Purpose: A better knowledge of the mechanisms and biomarkers of skin and lung damage in systemic sclerosis (SSc) related fibrosis remain a challenge. Our aim was…
Abstract Number: 1041 • 2019 ACR/ARP Annual Meeting
Computational Methods for Drug Repositioning of Systemic Sclerosis Using Gene Fold-Change and Network Analyses
Dillon Popovich¹, Michael Whitfield ², Yue Wang ³, Guoshuai Cai ⁴ and Mengqi Huang ⁵, ¹Geisel School of Medicine at Dartmouth College, Hanover, ²Geisel School of Medicine at Dartmouth College, Biomedical Data Science at Dartmouth College, Hanover, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Arnold school of Public Health, University of South Carolina, Columbia, SC, ⁵Geisel School of Medicine at Dartmouth College, Hanover, NH
Background/Purpose: Clinical trials with systemic sclerosis (SSc) patients have yet to lead to an FDA approved treatment. We have adopted a gene fold-change analysis called…
Abstract Number: 1042 • 2019 ACR/ARP Annual Meeting
Thy-1 (CD90) as a Novel Marker for Tracking in Vivo Skin Fibrosis
Benjamin Korman¹, Ananta Paine ², Stacey Duemmel ³, Marc Nuzzo ³ and Christopher Ritchlin ², ¹University of Rochester Medical Center, Rochester, NY, ²Division of Allergy, Immunology and Rheumatology, Center for Musculoskeletal Research, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA, Rochester, NY, ³University of Rochester, Rochester, NY
Background/Purpose: Thy-1 (CD90) is a cell surface marker which is found primarily on fibroblasts and whose expression has previously been shown to correlate with pathologic…
Abstract Number: 1043 • 2019 ACR/ARP Annual Meeting
The Metabolic Intermediate Alpha-Ketoglutarate Suppresses the TGFβ-driven Profibrotic Responses of Dermal Fibroblasts
Blaž Burja¹, Gabriela Kania ², Matija Tomšič ³, Tea Janko ³, Snezna Sodin-Semrl ³, Oliver Distler ⁴, Katja Lakota ³ and Mojca Frank-Bertoncelj ⁵, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ³Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, LJUBLJANA, Slovenia, ⁴Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland, ⁵University Hospital Zürich, Zürich, Switzerland
Background/Purpose: Metabolic perturbations are emerging as drivers of fibroblast activation in fibrosis. Transcriptomic analyses have shown the enrichment of glycolysis and suppression of tricarboxylic acid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].